Navigation Links
Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial
Date:6/19/2008

SYDNEY, Australia, June 19 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the company and the U.S. Food and Drug Administration (FDA) have reached agreement on the phase 3 registration trial of Bronchitol for bronchiectasis via the Special Protocol Assessment process.

The SPA process allows for FDA evaluation of a clinical trial protocol intended to form the primary basis of an efficacy claim in support of a New Drug Application, and provides an agreement that the study design, including trial size, clinical endpoints and/or data analyses are acceptable to the FDA.

Pharmaxis previously agreed on the trial design with the European regulatory agency (EMEA). This trial will therefore form the basis of a marketing application in both the U.S. and Europe.

The phase 3 trial has been designed in collaboration with internationally renowned experts in the field of bronchiectasis and will be a randomized, placebo controlled, double-blind investigation of Bronchitol twice daily in approximately 350 adults with bronchiectasis. Participants will be treated for 52 weeks and the primary endpoints are reduction in frequency of exacerbations and improvement in quality of life. Secondary endpoints include time to first exacerbation and duration of exacerbation. Additional secondary endpoints are antibiotic use, sputum volume, exercise tolerance and lung function measurements. The trial includes health economic analysis and will be conducted in centers across Europe and the U.S.

This trial is the second Phase III study to be undertaken for Bronchitol in bronchiectasis and follows the completion of a successful shorter trial reported last year.

Pharmaxis CEO, Alan Robertson, said the company was pleased to have concluded its discussions with the FDA and the EMEA.

''We believe this phase 3 trial design will allow us to thoroughly demonstrate the clinical benefits of Bronchitol in a patient populat
'/>"/>

SOURCE Pharmaxis Ltd.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Pharmaxis Establishes Named Patient Program for Bronchitol
2. Pharmaxis Long-Term Safety Study of Bronchitol Completes
3. Alseres Pharmaceuticals Concludes Enrollment in the Cethrin(R) Phase I/IIa Clinical Trial in Acute Spinal Cord Injury
4. FDA Concludes There is No Increased Risk of Cardiac Events for Patients Treated with omeprazole and NEXIUM(R) (esomeprazole magnesium)
5. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
6. Azor(TM) Reduces Blood Pressure in Difficult to Treat Special Populations
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Texas Heart(R) Institute at St. Lukes Episcopal Hospital Initiates First Clinical Trial in the World to Treat a Heart Attack Patient with a Special Stem Cell Type
9. Most Back Pain Could Be Cured Without Surgery or Drugs if Doctors Treated Muscles - Not the Spine - Says Leading Pain Specialist
10. Specialized Genasense(R) Clinical Trials Featured at AACR Meeting
11. Associated Foot & Ankle Specialists Enrolling Patients With Chronic Diabetic Foot Ulcers for MATRIX Clinical Trial

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)..., NEW YORK, Nov. 30 Reportlinker.... available in its catalogue: ,, Cardiac Defibr... ,, http://www.reportlinker.com/p0164315/Cardi...e-Report.html ,, Cardiovascular disease (CVD).... Sudden cardiac arrest survivors are prone to arr...
(Date:11/30/2009)..., NEW YORK, Nov. 30 Reportlinker.... available in its catalogue: ,, Outsourcing Op..., http://www.reportlinker.com/p0165747/Outsour..., Report Description ,, Medical devices form ... with an estimated size of $250 billion in 2009 an...
(Date:11/30/2009)...VINA, Calif., Nov. 30 StemCyte, In...ation agreement with Academia Sinica, the National...hods and Intellectual Property (IP) related to the...s method and IP was pioneered by a team led by Pro...inica. Professor Lin is currently the exclusive c...
Breaking Medicine Technology:Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 2Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 3Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 4Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 5Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 6Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 7Reportlinker Adds Cardiac Defibrillators - A Worldwide Market Intelligence Report 8Reportlinker Adds Outsourcing Opportunities in the Medical Device (2009 - 2014) 2Reportlinker Adds Outsourcing Opportunities in the Medical Device (2009 - 2014) 3Reportlinker Adds Outsourcing Opportunities in the Medical Device (2009 - 2014) 4Reportlinker Adds Outsourcing Opportunities in the Medical Device (2009 - 2014) 5Reportlinker Adds Outsourcing Opportunities in the Medical Device (2009 - 2014) 6Reportlinker Adds Outsourcing Opportunities in the Medical Device (2009 - 2014) 7Reportlinker Adds Outsourcing Opportunities in the Medical Device (2009 - 2014) 8Reportlinker Adds Outsourcing Opportunities in the Medical Device (2009 - 2014) 9StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke 2StemCyte Licenses Promising IP for Stem Cell Therapy to Treat Stroke 3Senators Kohl and Feingold Vote to Protect Americas Kids From Tobacco 48691 1Senators Kohl and Feingold Vote to Protect Americas Kids From Tobacco 48691 2Senators Baucus and Tester Vote to Protect Americas Kids From Tobacco 48688 1Senators Baucus and Tester Vote to Protect Americas Kids From Tobacco 48688 2Senators Levin and Stabenow Vote to Protect Americas Kids from Tobacco 48685 1Senators Levin and Stabenow Vote to Protect Americas Kids from Tobacco 48685 2
...Apr 11, 2007 - A comparison of,the long-term econo...es combined with symptom management versus symptom...ramer acetate,injection) was the most cost-effecti...iple sclerosis (RRMS). The study provides,the firs...eness of,multiple sclerosis (MS) therapies that in...
...Apr 11, 2007 - Gloucester,Pharmaceuticals, Inc., a...unced today that several abstracts covering,precli...e 2007,Annual Meeting of the American Association ... April 14-18, 2007. These,presentations will focus... multiple academic collaborators of the Company. F...
Other Medicine Technology:First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 2First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 3First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 4First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 5First Pharmacoeconomic Analysis with Long-Term Data Showed Copaxone,Was More Cost-Effective Than Interferon Beta Therapies for,Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) 6Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 2Gloucester Pharmaceuticals Announces Multiple Presentations of,Preclinical Romidepsin Data at American Association of Cancer,Research Annual Meeting 3
(Date:12/1/2009)...M. Marlon, MD was elected to the Stemedica Cell Te...f Directors at the Company’s November 20th B...ecember 1, 2009 -- Anthony M. Marlon, MD was elect...quo;Stemedica”) Board of Directors at the Co.... Howe, PhD, Executive Chairman for Stemedica made...
(Date:12/1/2009)...., Dec. 1 To date, hospitals have ...rse them for the $20 cost of the disposable sensor...ery. ,, Anesthesiologists have not told hospita...op dementia from routine anesthesia over-medicatio...id over-medication, message from their leaders bec...
(Date:12/1/2009)... Cell Therapeutics, Inc....ation at the 21st Annual Piper Jaffray Health Care...astern Time will be webcast live at www.cellthera...lace in Holmes 1 at the New York Palace Hotel, and...ntation. , , Piper Jaffray H...
(Date:12/1/2009)... at the annual meeting of the Radiological Society...ghly accurate means of identifying placenta accret... common condition that is the leading cause of dea..., "Due to the increase in cesarean sections and ... wall, coupled with women giving birth later in li...
(Date:12/1/2009)..., controlled clinical trial presented today at the...th America (RSNA) reveal that one in five patients...y blood to the legs and other parts of the body al...ease. , Peripheral arterial disease (PAD) occur...nd other substances, builds up in the arteries, li...
Breaking Medicine News(10 mins):Health News:Prominent Health Care Executive Joins Stemedica Board Of Directors 2Health News:Prominent Health Care Executive Joins Stemedica Board Of Directors 3Health News:5 Shocking Reasons Your Brain Isn't Worth Twenty Bucks Exposed 2Health News:MRI helps detect life-threatening pregnancy complication 2Health News:Severe asymptomatic heart disease may accompany narrowing in leg arteries 2
...e Mesothelioma Applied Research, Foundation (Meso... House, Energy and Commerce Committee on the "Bruc...t"(HR 3339), today, Thursday, February 28, 2008. T...oma and partner with the Meso Foundation in dev...
...in and European Commission Director General for En...russels an agreement which establishes the allocat...tribution to the implementation of the GMES Space ...be submitted for subscription by ESAs Member State...
... for one million children, WASHINGTON, Feb. 28 T... the recognized leader in children,s oral health, ...ead Start (OHS) to help combat,children,s tooth de...or one million children enrolled annually,in OHS p...
...ation Program This Spring, LOVELAND, Ohio, Feb. 2...a non-profit 501(c)(3) organization that promotes,...e evaluations of,population health management prog...rrent Board members Thomas Wilson,Ph.D., DrPH (Cha...
...r,groups said today that they will continue their ...tem cells held by the Wisconsin Alumni,Research Fo...tent Office,allowing three amended claims in one o...later final decision,by the examiner supporting th...
...e distinctive ability of mothers to identify the c...e, where it is critical to the survival of these o...ctive ability of mothers to recognize and respond ...a very limited understanding of how the maternal b...
Other Medicine News:Health News:Leading Asbestos-Cancer Group Urges Congress to Partner with Them and Support Funding Provisions in Asbestos Ban Legislation 2Health News:Leading Asbestos-Cancer Group Urges Congress to Partner with Them and Support Funding Provisions in Asbestos Ban Legislation 3Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 2Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 3Health News:AAPD Announces Partnership With Head Start to Address Childhood Epidemic 2Health News:AAPD Announces Partnership With Head Start to Address Childhood Epidemic 3Health News:Population Health Impact Institute Announces New Board Members 2Health News:Consumer Groups Will Continue to Press Stem Cell Patent Challenge 2Health News:Maternal love: How a mother's brain responds to her infant 2
AIA-600 II
...c Antigen Rapid Test Strip and Device (Whole Blood... device formats for the semi-quantitative detectio...e available with 4 ng/mL or 3 ng/mL cut-off values...y can be performed using serum, plasma or whole bl...
... Contrast Sensitivity. The Optec 6500 controls bot...or accurate and repeatable testing results. Day/Ni...nance Comply with International Standards and all ...ntrolled and Continually Calibrated. The Optec 650...
Functional Acuity Contrast Test
Medicine Products: